Les Meilleures Cliniques et Coûts des traitements de myasthénie en République de Corée 2026

Major university hospitals in Seoul specialize in Myasthenia Gravis through dedicated neurology clinics. Facilities like Seoul National University Hospital and Samsung Medical Center offer multidisciplinary care. These centers integrate advanced diagnostic tools and immunotherapy protocols. They provide comprehensive management for complex autoimmune neuromuscular disorders.

• Therapeutic options: Clinics offer plasmapheresis, selective apheresis, and IVIG therapy.
• Specialized units: Seoul National University Hospital features a dedicated Neuroscience Center.
• Advanced diagnostics: Protocols include EMG, repetitive nerve stimulation, and tumor marker tests.
• Surgical support: Thoracic surgeons perform thymectomy using minimally invasive robotic techniques.

Bookimed Expert Insight: Seoul National University Bundang Hospital utilizes the BESTcare system to prevent medical errors. This is crucial for MG patients who must avoid specific contra-indicated medications. High-volume centers like SNUH treat over 10,700 patients daily. This scale ensures neurologists see rare MG subtypes frequently. Many facilities also offer integrated pediatric and obstetric support for specialized cases.

Patient Consensus: Patients note it is helpful to consult major academic centers for rare autoimmune issues. They often suggest checking with local associations for specific hospital referrals in Korea.

South Korea provides both standard and next-generation biological therapies for Myasthenia Gravis. Available protocols include monoclonal antibodies like Efgartigimod and Complement C5 inhibitors. Major centers specialized in neurology utilize advanced apheresis and therapeutic plasma exchange to manage refractory cases effectively.

• Systemic therapy: MFDS-approved pyridostigmine and corticosteroids serve as primary frontline management.
• Advanced biologics: FcRn blockers including Efgartigimod and Rozanolixizumab target harmful autoantibodies.
• Targeted inhibitors: Complement C5 inhibitors like Zilucoplan are available for antibody-positive gMG.
• Surgical intervention: Thymectomy procedures are performed using robotic systems at digitalized hospitals.

Bookimed Expert Insight: Korea excels in digitalizing neurological care to prevent medical errors. Seoul National University Bundang Hospital uses the unique BESTcare system. This system tracks treatment protocols for 1,500,000 yearly patients to ensure safety during intensive therapies like plasmapheresis. Large facilities like SNUH serve over 10,000 daily patients, offering vast clinical experience in rare neuromuscular disorders.

Patient Consensus: Patients note it is important to connect with specialized neurology societies in Korea. They emphasize seeking hospitals with dedicated neuromuscular departments for the newest biological drug availability.

South Korean neurologists manage refractory or MuSK-antibody myasthenia gravis using advanced immunosuppression and plasma exchange. Treatment often bypasses thymectomy, which is less effective for this subtype. Centers utilize rituximab off-label while monitoring new approvals like efgartigimod for specific patient groups.

• Systemic therapy: Doctors prescribe tacrolimus, cyclosporine, or mycophenolate for steroid-resistant cases.
• Rescue protocols: Plasmapheresis is the preferred emergency intervention for MuSK-positive patients.
• Diagnostic process: Testing includes extended blood analysis and specialized antibody screens via neurology.
• Clinical infrastructure: Digitalized centers like Seoul National University Bundang Hospital provide high-volume care.

Bookimed Expert Insight: While South Korea ranks 4th globally in medical infrastructure, MuSK antibody testing often requires sending samples abroad. This creates a 30-day window before confirming the diagnosis. International patients should bring existing antibody reports to Seoul National University Hospital to accelerate the start of targeted immunosuppression protocols.

Patient Consensus: Patients note it is important to confirm drug reimbursement status early. Many emphasize that specialized neurology consultations in Seoul are essential for accessing off-label biologic treatments.

Korean National Health Insurance covers most standard myasthenia treatments. This condition is classified as a Rare Intractable Disease. This status significantly reduces out-of-pocket costs for registered patients. Coverage includes first-line drugs like pyridostigmine. It also covers corticosteroids and most immunosuppressants.

• Acute interventions: Plasmapheresis and IVIg are reimbursed during acute myasthenic crises.
• Biological therapies: Ultomiris is covered for refractory cases meeting specific clinical criteria.
• Maintenance exclusion: Long-term maintenance IVIg is generally excluded from standard insurance benefits.
• Specific restrictions: Rituximab is currently not eligible for reimbursement for myasthenia gravis.

Bookimed Expert Insight: Patients should prioritize digitalized facilities like Seoul National University Bundang Hospital. These centers use the BESTcare system to manage complex health insurance documentation. Myasthenia management involves many specialists and recurring prescriptions. Large public institutions handle rare disease registrations more efficiently than smaller private clinics. This ensures faster access to the 90% cost reduction for rare diseases.